



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



## Prazosin-d<sub>8</sub> Item No. 29094

**CAS Registry No.:** 1006717-55-0  
**Formal Name:** [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl-2,2,3,3,5,5,6,6-d<sub>8</sub>]-2-furanyl-methanone  
**MF:** C<sub>19</sub>H<sub>13</sub>D<sub>8</sub>N<sub>5</sub>O<sub>4</sub>  
**FW:** 391.5  
**Chemical Purity:** ≥98% (Prazosin)  
**Deuterium Incorporation:** ≥99% deuterated forms (d<sub>1</sub>-d<sub>8</sub>); ≤1% d<sub>0</sub>  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Prazosin-d<sub>8</sub> is intended for use as an internal standard for the quantification of prazosin (Item No. 15023) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Prazosin-d<sub>8</sub> is supplied as a solid. A stock solution may be made by dissolving the prazosin-d<sub>8</sub> in the solvent of choice, which should be purged with an inert gas. Prazosin-d<sub>8</sub> is soluble in chloroform. Prazosin-d<sub>8</sub> is slightly soluble in methanol.

### Description

Prazosin is an antagonist of  $\alpha_1$ -adrenergic receptors ( $\alpha_1$ -ARs).<sup>1,2</sup> It selectively binds to  $\alpha_{1A}$ -ARs with  $K_i$  values of 0.2, 0.25, and 0.32 nM for the human recombinant  $\alpha_{1A}$ -,  $\alpha_{1B}$ -, and  $\alpha_{1D}$ -ARs, respectively, over  $\alpha_2$ -ARs ( $K_s = 340$  and 3.7 nM in  $\alpha_{2A}$ -AR-expressing HT-29 cells and  $\alpha_{2B}$ -AR-expressing NG108 cells, respectively).<sup>3,4</sup> It also binds to melatonin receptor 3 (MT<sub>3</sub>) in hamster brain membranes ( $IC_{50} = 7.8$  nM).<sup>5</sup> Prazosin inhibits peripheral and central postsynaptic  $\alpha_1$ -ARs with  $IC_{50}$  values of 0.2 and 1.7 nM in isolated dog aorta and rat brain, respectively.<sup>1</sup> It decreases diastolic blood pressure in normal, renal hypertensive, and spontaneously hypertensive rats when administered at a dose of 1 mg/kg.<sup>6</sup> Prazosin (1.5 mg/kg) increases the number of entries and percentage of time spent in the open arms of the elevated plus maze, indicating anxiolytic-like activity, in alcohol-consuming rats and also reduces alcohol intake and alcohol-seeking behavior in alcohol-preferring rats.<sup>7,8</sup>

### References

1. Nagatomo, T., Tsuchihashi, H., Sasaki, S., et al. *Jpn. J. Pharmacol.* **37(2)**, 181-187 (1985).
2. Kristek, F. and Koprdoval, R. *J. Physiol. Pharmacol.* **62(3)**, 295-301 (2011).
3. Leiker, A.J., DeGraff, W., Choudhuri, R., et al. *Clin. Cancer Res.* **21(12)**, 2792-2801 (2015).
4. Bylund, D.B. and Ray-Prenger, C. *J. Pharmacol. Exp. Ther.* **251(2)**, 640-644 (1989).
5. Paul, P., Lahaye, C., Delagrang, P., et al. *J. Pharmacol. Exp. Ther.* **290(1)**, 334-340 (1999).
6. Fernandes, M., Smith, I.S., Weder, A., et al. *Clin. Sci. Mol. Med. Suppl.* **48**, 181s-184s (1975).
7. Verplaetse, T.L., Rasmussen, D.D., Froehlich, J.C., et al. *Alcohol Clin. Exp. Res.* **36(5)**, 881-886 (2012).
8. Skelly, M.J. and Weiner, J.L. *Brain Behav.* **4(4)**, 468-483 (2014).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/17/2020

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM